

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

		•	. 4		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	-	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/344,382	06/25/1999	SHUNICHI SOMA	)	050499/0101	9000
75	90 11/19/2001	•			
FOLEY & LARDNER 3000 K STREET NW P O BOX 25696 WASHINGTON, DC 200078696		:		EXAM	NER
			, , ,	ROMEO, DAVID S	
			ſ	ART UNIT	PAPER NUMBER
			•	1647	15
		•	. ]	DATE MAILED: 11/19/2001	()

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/344,382	SOMA ET AL.				
	Office Action Summary	Examiner	Art Unit				
		David S Romeo	1647				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - Ext afte - If th - If N - Fail - Any	HORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. ensions of time may be available under the provisions of 37 CFR 1.13 or SIX (6) MONTHS from the mailing date of this communication. He period for reply specified above is less than thirty (30) days, a reply of period for reply is specified above, the maximum statutory period vure to reply within the set or extended period for reply will, by statute or reply received by the Office later than three months after the mailing the patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply within the statutory minimum of thirty (30 will apply and will expire SIX (6) MONTHS, cause the application to become ABANI	be timely filed  0) days will be considered timely.  6 from the mailing date of this communication.  DONED (35 U.S.C. § 133).				
1)[🛛	Responsive to communication(s) filed on 07.5	September 2001 .					
2a) <u></u>	This action is <b>FINAL</b> . 2b)⊠ Th	is action is non-final.	·				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposi	tion of Claims						
4)🛛	4) Claim(s) 22-50 is/are pending in the application.						
4a) Of the above claim(s) 29-42 is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) 22-50 are subject to restriction and/or	election requirement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachme	nt(s)						
2) 🔲 Noti	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Infor	nmary (PTO-413) Paper No(s) mal Patent Application (PTO-152)				

Art Unit: 1647

5

10

15

## **DETAILED ACTION**

1. The amendment filed 09/07/2001 (Paper No. 10) has been entered. Claims 23-50 are pending. Claims 29-42 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 4.

## Election/Restriction

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 22-28, 43, 45, 47-50, to the extent that they are drawn to a remedy comprising administering a PTH hormone or a fragment thereof, classified in class 514, subclass 12.
  - II. Claims 22, 43, 44, 46-50, to the extent that they are drawn to a remedy comprising administering a PTH hormone derivative wherein said derivative is PTH substituted at amino acid 8 with leucine or nor leucine, classified in class 514, subclass 12.
  - III. Claims 22, 43, 44, 46-50, to the extent that they are drawn to a remedy comprising administering a PTH hormone derivative wherein said derivative is PTH substituted at amino acid 18 with leucine or nor leucine, classified in class 514, subclass 12.

Art Unit: 1647

5

IV. Claims 22, 43, 44, 46-50, to the extent that they are drawn to a remedy comprising administering a PTH hormone derivative wherein said derivative is PTH substituted at amino acid 34 with tyrosine, classified in class 514, subclass 12.

IV. Claims 22, 43, 47-50, to the extent that they are drawn to a remedy comprising administering a PTH hormone derivative wherein said derivative is a peptide constructed by adding one or more amino acids to PTH, classified in class 514, subclass 12.

- 3. The inventions are distinct, each from the other because of the following reasons:
- a. The following pairwise combinations of methods are independent and distinct,
   wherein each member of a pair uses different materials and/or process steps: I and each of II-IV;
   II and each of III-IV; III and each of IV.
  - 4. Because these inventions are distinct for the reasons given above and the searches required for the each of the different materials are not coextensive, restriction for examination purposes as indicated is proper.
- 5. This application contains claims directed to the following patentably distinct species of the claimed invention: administering multiple times or administering continuously.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 22-28, 43-50 are generic.

Art Unit: 1647

5

10

15

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

For each of said administering multiple times or administering continuously this application contains claims directed to the following patentably distinct species of the claimed invention: administration in a preparation comprising a sustained release base, administered systemically, administered in a composition comprising polyethylene glycol.

Art Unit: 1647

5

10

15

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 22-28, 43-50 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

For administration in a preparation comprising a sustained release base this application contains claims directed to the following patentably distinct species of the claimed invention: collagen pellets, polylactic acid bases, hydroxyapatite cement, and alginic acid gel.

Art Unit: 1647

5

10

15

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 22, 47, 48 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

6. This application contains claims directed to the following patentably distinct species of the claimed invention: PTH(1-34), PTH(1-37), PTH(1-38), PTH(1-64), PTH(1-84).

Art Unit: 1647

5

10

15

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 22-28, 43, 45, 47-50 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1647

8. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

5 fee required under 37 CFR 1.17(i).

ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (703) 305-4050. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 7:30 A.M. TO 4:00 P.M.

IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (703) 308-4623.

OFFICIAL PAPERS FILED BY FAX SHOULD BE DIRECTED TO (703) 308-4242.

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (703) 308-0294.

ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING

SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.

15

10

DAVID ROMEO
PRIMARY EXAMINER
ART UNIT 1647

NOVEMBER 17, 2001